Roth Capital Downgrades Zynerba Pharmaceuticals (ZYNE) to Neutral
Tweet
Share
E-mailGet Alerts ZYNE Hot Sheet
Price: $1.30 --0%
Rating Summary:
4 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 23
Rating Summary:
4 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 23
Join SI Premium – FREE
Roth Capital downgraded Zynerba Pharmaceuticals (NASDAQ: ZYNE) from Buy to Neutral with a price target of $7.00 (from $30.00).
For an analyst ratings summary and ratings history on Zynerba Pharmaceuticals click here. For more ratings news on Zynerba Pharmaceuticals click here.
Shares of Zynerba Pharmaceuticals closed at $6.67 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Limbach Holdings (LMB) to Underweight
- Nippon Yusen Kabushiki Kaisha (9101:JP) (NPNYY) PT Raised to JPY7,000 at JPMorgan
- Oxford Nanopore (ONT:LN) (ONTTF) PT Raised to GBP1.82 at Barclays
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
